The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The plasma lipid transfer proteins promote the exchange of neutral lipids and phospholipids between the plasma lipoproteins. Cholesteryl ester transfer protein (CETP) facilitates the removal of cholesteryl esters from HDL and thus reduces HDL levels, while phospholipid transfer protein (PLTP) promotes the transfer of phospholipids from triglyceride-rich lipoproteins into HDL and increases HDL levels. Studies in transgenic mouse models and in humans with rare genetic deficiencies (CETP) or common genetic variants (CETP and PLTP) highlight the central role of these molecules in regulating HDL levels. Human CETP deficiency is associated with dramatic elevations of HDL cholesterol and apolipoprotein A-I levels, while PLTP variants with increased expression are associated with higher HDL levels. A recent meta-analysis suggests that common CETP alleles causing reduced CETP and increased HDL levels are associated with reduced coronary heart disease. The failure of a clinical trial with the CETP inhibitor torcetrapib may have been related in part to off-target toxicity. Ongoing phase 3 clinical trials with other CETP inhibitors may help to clarify if this strategy can ultimately be successful in the treatment of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 2×
“Unfortunately, a large phase III clinical trial called ILLUMINATE involving torcetrapib, was stopped prematurely as a result of an excess of deaths and cardiovascular disease in the group receiving torcetrapib and atorvastatin compared to atorvastatin alone (26).”
BackgroundSelf-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774 · cited 1×
“Clinical trials in humans using CETP inhibitors such as torcetrapib have shown marked increases in HDL, and moderate reductions in LDL (25).”
BackgroundPolymorphisms Associated with Cholesterol and Risk of Cardiovascular Events
Kathiresan, S., Melander, O., Anevski, D., Guiducci, C., Burtt, N. P., Roos, C., Hirschhorn, J. N., Berglund, G., Hedblad, B., Groop, L., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706728 · Cited by 696
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Self-citationJiang, X.-C., Li, Z., Liu, R., Yang, X. P., Pan, M., Lagrost, L., Fisher, E. A., & Williams, K. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500007200 · Cited by 102 · cited 1×
“Alteration of vitamin E content of liver may also contribute regulating apoB lipoprotein production, perhaps by influencing reactive oxygen species generation and efficiency of insulin signaling in hepatocytes (40).”
BackgroundSelf-citation
Cited by
High-density lipoprotein heterogeneity and function in reverse cholesterol transport
Rothblat, G. H., & Phillips, M. C. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328338472d · Cited by 340
Genetic determinants of plasma triglycerides
Johansen, C. T., Kathiresan, S., & Hegele, R. A. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r009720 · Cited by 263
High Density Lipoprotein Structure–Function and Role in Reverse Cholesterol Transport
Lund-Katz, S., & Phillips, M. C. (2010) · Subcellular Biochemistry · doi:10.1007/978-90-481-8622-8_7 · Cited by 262
Kones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259
Effects of curcumin on HDL functionality
Ganjali, S., Blesso, C. N., Banach, M., Pirro, M., Majeed, M., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.008 · Cited by 186
Metadata
- Authors
- Masson, D., Jiang, X.-C., Lagrost, L., & Tall, A. R.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 50
- Pages
- S201-S206
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2016936415
- Cited by
- 131
- References
- 5
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. https://app.cochat.ai/papers/10.1194/jlr.r800061-jlr200
- The paper
- Masson, D., Jiang, X.-C., Lagrost, L., & Tall, A. R. (2009). The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. Journal of Lipid Research. https://doi.org/10.1194/jlr.r800061-jlr200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.